Celltrion Eyes Remsima SC Launches In Canada And Australia
Company On Track To Launch At Least One Biosimilar Every Year By 2030
Celltrion is focused on launching subcutaneous infliximab in Canada and Australia, and adalimumab in Europe • Source: Alamy 
